PROTXX, University of Alberta Collaborate to Develop Remote Healthcare Platform for MS PatientsThe University of Alberta and PROTXX are collaborating to develop wearable sensors for people with multiple sclerosis (MS) and advance a remote healthcare platform that facilitates ... Read more
Osmotica Amends NDA for Arbaclofen ER to Treat MS SpasticityOsmotica Pharmaceuticals has submitted an amended new drug application (NDA) to the U.S. Food and Drug Administration (FDA) requesting the approval of arbaclofen extended ... Read more
Anxiety and Depression Linked to RRMS Relapse Risk, Study FindsComorbidities such as anxiety and depression are associated with a significantly increased risk of relapse in people with relapsing-remitting multiple sclerosis (RRMS), ... Read more
Subscribe to our mailing list
Get regular updates delivered to your email box.
Thanks! Please check your email for a confirmation email.
A first patient has been enrolled in a single-site trial to evaluate the potential of electrical stimulation, called Electroceutical Therapy, in reducing brain injury, Endonovo Therapeutics, the therapy’s developer, announced. Electroceutical Therapy is a non-invasive and wearable electronic device that uses pulsed ... Read more